Cheng Mo

发表

2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors.

Yong Xu, J. Smaill, Xiaoyun Lu, 2017, ACS medicinal chemistry letters.

Design and Optimization of 3'-(Imidazo[1,2-a]pyrazin-3-yl)-[1,1'-biphenyl]-3-carboxamides as Selective DDR1 Inhibitors.

Yong Xu, Xiaoyun Lu, Zheng-chao Tu, 2020, ACS medicinal chemistry letters.

Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors

Yong Xu, A. Bullock, L. Yao, 2016, Journal of medicinal chemistry.

Discovery of HPG1860, a Structurally Novel Nonbile Acid FXR Agonist Currently in Clinical Development for the Treatment of Nonalcoholic Steatohepatitis.

Xin-jie Chu, Yating Xiong, Xiaodong Xu, 2023, Journal of medicinal chemistry.